A leader in
ophthalmic
academics
Pushing the state of the art forward.
A leader in
ophthalmic
innovation
Pushing the state of the art forward.
A leader in
ophthalmic
surgery
Pushing the state of the art forward.
Innovations
Known as one of the most prolific ophthalmic inventors and entrepreneurs, Dr. Ianchulev has been at the forefront of ophthalmic innovation with many FDA-approved medical products. His technologies have transformed the ophthalmic field and are impacting eye care around the globe.
Ora
Wavered, Inc.
Acquired by Novartis, Inc.
Dr. Ianchulev invented intraoperative aberrometry - the first intra-operative biometry device for surgical intervention in ophthalmology. The ORA system uses infrared laser aberrometry for high-precision cataract surgery. It has been used in more than 3 million cataract surgeries worldwide.
miLOOP
Iantech, Inc.
Acquired by Zeiss, Inc.
Dr. Ianchulev is the inventor of the miLOOP and founder of Iantech, Inc. miLOOP® is a memory-shaped, super-elastic nitinol fragmentation device for micro-interventional cataract surgery.
Optejet
Eyenovia, Inc
IPO
Dr. Ianchulev led the development of the first FDA-approved pipette-free topical ophthalmic delivery system as well as the first smart, micro-dosing and horizontal-delivery technology in eye care.
miCOR
Iantech, Inc.
Acquired by Zeiss, Inc.
Dr. Ianchulev founded Iantech Inc. in 2014 to create a first-in-class micro-interventional platform for subsonic, cavitation-free lensectomy and cataract surgery.
CycloPen
Iantrek, Inc.
Private, Venture-backed
Dr. Ianchulev is the founder of Iantrek, Inc. and the inventor of the CycloPen supraciliary micro-interventional technology for glaucoma surgery, which received FDA approval in 2021.
C.Rex
Iantrek, Inc.
Private, Venture-backed
Dr. Ianchulev is the founder of Iantrek, Inc. and the inventor of the C-Rex gonio-interventional technology for glaucoma surgery, which received FDA approval in 2021.
Macustat & Peristat
RemoniHealth, Inc
Private
More than 20 years ago, Dr. Ianchulev developed the first 100% virtual diagnostic devices (Peristat, Macustat) in eye care for remote vision testing and diagnosis of retinal and optic nerve diseases.
RemoniHealth
RemoniHealth, Inc
Private
Dr. Ianchulev co-founded RemoniHealth, Inc - the first vision-as-a-service (VaaS) platform for remote patient monitoring and remote care management.
AlloFlo Biostent
Iantrek, Inc.
Private, venture-backed
The AlloStent is the first bio-stent made entirely of biological material with no implantable hardware. It is used in the interventional treatment of glaucoma.
CyPASS
Transcend Medical, Inc.
Acquired By Novartis
The first suprachoroidal MIGS stent to receive FDA approval. Used in thousands of patients worldwide.
Preceyes Robotics
Preceyes, Inc.
Acquired by Zeiss, Inc.
As a key clinical collaborator and founding board member of Preceyes Robotics, Inc,. Dr. Ianchulev’s pioneering work lead to the first introduction of a clinical robotic system to the US in 2020 at the New York Eye and Ear Hospital as well as the first acquisition of a robotics company in ophthalmic surgery.
Lucentis
Genentech, Inc
While at Genentech, Dr. Ianchulev lead the clinical research for Lucentis and the initial clinical efforts for one of the first bi-specific antibodies Vabyssmo.
Propionic Aciduria Optic Neuropathy
In 2002, Dr. Ianchulev was the first to describe the syndrome of propionic acuduria and optic neuropathy in children.
Office Based Cataract Surgery
With his seminal population health research on office based eye surgery and his 2016 publication of 21,000 cases, Dr. Ianchulev pioneered a new surgical paradigm with tremendous efficiency and cost-savings.
Eye Surgeon
Dr. Ianchulev is a pioneering inventor in the field of eye surgery. He is responsible for groundbreaking surgical innovations such as high-precision, infrared laser-guided cataract surgery with intra-operative aberrometry, the first micro-interventional systems for cataract surgery with the miLOOP and miCOR technologies, the first supraciliary micro-stent for glaucoma, and the first Nitinol super-elastic filament technology for cataract and glaucoma interventions.
Dr. Ianchulev has also pioneered an entire category of bio-interventional ophthalmic surgery with the first implantable biologic micro-stent made of hardware-free, 100% allogeneic bio-tissue material. Dr. Ianchulev is an ophthalmic surgeon with subspecialty training in glaucoma and has performed thousands of surgical procedures restoring sight in patients all over the world.
Background
Dr. lanchulev received both his medical degree (MD) and a Master of Public Health (MPH) degree from Harvard University and completed his specialty training at the Doheny Eye Institute, University of Southern California. He is currently a Professor of Ophthalmology at New York Eye and Ear of Mount Sinai where he also directs the program for technology and innovation.
Procedures
Dr. lanchulev has successfully performed over 4,000 eye surgeries, improving the quality of life for his patients.
Humanitarian
Dr. lanchulev has led many sight-saving humanitarian missions in Africa and Latin America. He has donated his technologies and surgical talent for global outreach in the fight against cataract and glaucoma blindness.
Academic
As a Professor of Ophthalmology, Dr. Ianchulev is recognized for his accomplishments and work in teaching and research. His innovative research has led to patents, licenses, and commercial products and has been cited by more than 4,000 peer-reviewed publications. He was an invited expert by the US Congress on matters of medical innovation and FDA regulation.
Innovations Product Art Gallery
Dr. Ianchulev’s technology artwork, designs, and campaign ads
Media
Media coverage and talks at national and international conferences
2024 Keynote Address Glaucoma 360
2024 Keynote Address Glaucoma 360
NYEE 2024 Specialty Report
NYEE 2024 Specialty Report
Glaucoma 360 Presentation
Glaucoma 360 Presentation
Contact
Reach out to Dr. Ianchulev here.